Malaria and Babesia
PLASMODIUM spp.
- Exposure history, such as travel, recent transfusion, or living in close proximity to an international airport.
- Non-falciparum malaria: chills and fever spikes, followed by defervescence and fatigue; symptoms may be cyclical every 48-72 hours.
- Falciparum malaria: fever spikes and chills, often non-cyclical and associated with rapidly progressive systemic symptoms.
- Detection and identification of a Plasmodium species in a thick and thin blood smear, respectively.
- Molecular detection of P. falciparum histidine-rich protein by enzyme-linked immunosorbent assay (ELISA) or Plasmodium DNA by polymerase chain reaction (PCR), followed by speciation using probe hybridization or DNA sequencing.
These features illustrate how exposure history, clinical fever patterns, and laboratory testing work together to support the diagnosis of malaria. Prompt recognition is important because some forms, especially P. falciparum, can progress quickly and become life-threatening in non-immune individuals.
General Considerations
Epidemiology
Malaria, a disease of antiquity, was recognized by Hippocrates and was described possibly as early as 1700 BC in ancient Chinese texts. Malaria is a global disease that occurs most commonly in the tropics; however, transmission may also occur in temperate zones. In the 19th and early 20th centuries, Plasmodium species were widely distributed in the United States. This distribution included the southern United States, the Mississippi River Valley, and extensions as far north as Minnesota and Michigan.
Today, primarily in tropical areas, Plasmodium parasites continue to cause more than 100 million cases of malaria per year. This results in an estimated 1-2 million deaths annually, many of whom are children. In fact, more than 90% of severe, life-threatening malaria occurs in children. The distribution of the mosquito vector and the prevalence of disease in Indigenous populations are the major factors that determine the distribution of the Plasmodium parasite.
Mosquito-infested areas, such as swamps, have long been associated with high attack rates of malaria. Environments that support long-standing, stagnant water promote mosquito breeding. Currently, endemic areas include parts of the Caribbean, northern South America, Central America, parts of Africa, India, parts of Australia, Southeast Asia, and many of the Asian Pacific islands.
Malaria also occurs sporadically in non-endemic areas. In many instances, this represents imported, latent disease. Malarial relapses may present months after travellers have returned from endemic areas. These patients have usually been incompletely treated or have taken insufficient chemoprophylaxis.
Relapsing malaria is caused by reactivation of the latent hypnozoite phase of P. vivax or P. ovale. Patients who develop malaria may be treated with a wide variety of agents. The most commonly used antimalarial drugs, chloroquine and mefloquine, are effective against the symptomatic, erythrocytic phase of P. vivax and P. ovale and may result in apparent cures. These drugs, however, are ineffective against the hepatic hypnozoites. Patients treated in this manner are incompletely treated and are at risk for malarial relapse.
Some patients may report never having had a previous episode of malaria. However, specific questioning often reveals a brief lapse in chemoprophylaxis. A lapse in chemoprophylaxis may result in a window period of subprophylactic drug levels. During this window period, sporozoites injected by an infected mosquito during a blood meal may reach and infect the liver. Any parasites (merozoites) that emerge from the liver while the patient is taking chemoprophylaxis are rapidly killed, and the patient remains asymptomatic. Hypnozoites, however, may become active months after return from an endemic area, long after chemoprophylaxis has been stopped. Proper identification of P. vivax and P. ovale is important because only these species form hepatic hypnozoites and may result in malarial relapse.
In non-endemic areas, cases of so-called "airport malaria" may occur. Mosquito vectors from endemic areas may be transported with airline cargo. An individual in a non-endemic area who lives in close proximity to an airport may become infected if bitten by these mosquitoes. The propagation of the parasite is usually not sustained in the environment. This is either because of a lack of a suitable mosquito host or because of the low number of parasites in the community. When the prevalence of malaria is low, the probability of a mosquito ingesting gametocytes is very low. In addition, if infected mosquitoes are rare, they may take a non-human blood meal and thereby disrupt the parasitic cycle.
Mosquito transmission is the most common route of infection, but other modes of transmission exist. Transmission may result from intravenous drug use (shared needles) or blood transfusion. In these instances, only the erythrocytic cycle is established, because hepatocytes can be infected only by the sporozoite form of the parasite.
Microbiology
Numerous Plasmodium species exist; however, only four species are known to infect humans. These species are P. falciparum, P. vivax, P. ovale, and P. malariae. Worldwide, P. vivax causes the vast majority of disease (approximately 80%), followed by P. falciparum (approximately 15%).

Depending on the infecting plasmodial organism, malaria differs in severity, complications, prognosis, and treatment. Therefore, with the exception of differentiating P. vivax from P. ovale, it is important to promptly and properly speciate the organism. Malaria is typically separated into two disease types: falciparum and non-falciparum. This distinction emphasizes the severity of P. falciparum malaria, which is a medical emergency in the non-immune individual. Among the non-falciparum species, it is important to distinguish P. vivax and P. ovale from P. malariae. The former two species have a dormant hepatic stage, which requires separate treatment to avoid malarial relapse.
Identification of Plasmodium organisms and differentiation of the various species remain based primarily on parasite morphology in Giemsa-stained blood preparations. Organism detection is the initial task in the laboratory diagnosis of malaria. This is accomplished by examining a thick blood preparation. Examination of a thick preparation is an important part of assessing blood for parasites and should not be bypassed unless plasmodia have already been detected in a routine peripheral blood smear. The thick preparation increases the diagnostic yield compared with examination of thin blood smears. In the thick preparation, a larger volume of blood can be screened more rapidly. This becomes critical for detecting low-grade parasitemia, such as that associated with long-term P. malariae infections or early in the course of malaria.
Thick preparations are made by placing 1-2 drops of the patient's blood together on a glass slide. The blood is not smeared and is allowed to air dry. The slide is then stained by the Giemsa method, without methanol fixation. The unfixed erythrocytes (RBCs) lyse in the hypotonic stain solution. The stained preparation is first examined under 10× magnification, then under 100× oil immersion.
Filariasis is endemic to many of the same regions that harbour malaria parasites and may cause cyclical fevers. The microfilariae are easily detected in thick blood preparations at 10× magnification. The purpose of the 100× oil immersion examination is to detect Plasmodium species.
In Giemsa-stained preparations, Plasmodium parasites have red chromatin and light-blue cytoplasm. The ring forms of any Plasmodium species and the gametocytes of P. falciparum are the structures most easily identified in thick preparations. Practice is required to differentiate Plasmodium amoeboid and schizont forms from platelets and debris. Thin blood smears must be examined if thick preparations demonstrate the presence of a Plasmodium species.
The methanol-fixed, Giemsa-stained thin blood smear is used for Plasmodium speciation. Useful criteria for differentiating Plasmodium species are summarized in Table 1. However, it is rare for all of these morphologic features to be present in a blood smear. Differentiation must be made using all available information. The morphologic criteria useful in differentiating Plasmodium species are discussed briefly.
The crescent-shaped gametocyte is pathognomonic of P. falciparum, but, unfortunately, this structure is not always present. Features in the peripheral smear that, in combination, may be used to identify P. falciparum include the presence of small, delicate-appearing ring trophozoites; infected erythrocytes that remain normocytic; and the presence of predominantly ring trophozoites, with a conspicuous absence or relative rarity of more advanced forms. High parasitemia and erythrocytes infected with multiple organisms are more commonly seen in patients with falciparum malaria. Appliqué forms and two chromatin centres per ring trophozoite are also suggestive of P. falciparum, but may be present in other Plasmodium species.
Unlike P. falciparum, P. vivax and P. ovale produce thicker and larger ring trophozoites; infected RBCs become macrocytic; and advanced forms, such as amoeboid trophozoites, schizonts, or both, are usually present in the peripheral smear. In an appropriately pH-balanced Giemsa stain (pH 6.8-7.0), RBCs infected by P. vivax or P. ovale may demonstrate fine eosinophilic stippling. This fine stippling should not be confused with larger, coarse, comma-shaped dots (Maurer's dots) that may be present in P. falciparum-infected erythrocytes. Appliqué forms are typically not present in P. vivax- or P. ovale-infected erythrocytes, and ring trophozoites usually have only a single chromatin dot. Occasionally, more than one trophozoite may be present per erythrocyte. Although P. vivax and P. ovale can be differentiated from one another, this is difficult and requires parasitology expertise. Differentiation of P. vivax and P. ovale is usually not indicated or performed, because the disease caused by these organisms is similar and the treatment is identical.
P. malariae-infected RBCs invariably contain advanced plasmodial forms and, like P. vivax and P. ovale, the ring forms produced are thick. However, stippling is not observed. Specialized advanced forms, such as the band form and the basket form, are highly suggestive of P. malariae. Like P. falciparum, ring trophozoites may occasionally contain two chromatin dots, and infected RBCs remain normocytic.
Coinfection with more than one Plasmodium species may occur. Coinfections, especially in individuals who live in areas endemic for more than one Plasmodium species, are relatively common. These mixed infections are important to detect because of differences in disease prognosis and therapy.
Pathogenesis
The definitive host and vector for the Plasmodium parasite is the female Anopheles mosquito. Asexual reproduction and gametogenesis occur in the human intermediate host. The parasitic life cycle is similar for all Plasmodium species. However, important differences do exist.
Infecting sporozoites originate from the salivary gland of the female Anopheles mosquito. They are transmitted into the human during a blood meal. The sporozoites then migrate via the bloodstream to the liver, where hepatocytes become infected. In the liver, tissue schizonts are formed. These contain numerous, asexually derived merozoites. From a single sporozoite, this phase of asexual reproduction results in a 10,000- to 30,000-fold organism amplification. This portion of the asexual reproduction cycle is common to all Plasmodium species.
Production of dormant hepatic hypnozoites is unique to the life cycle of P. vivax and P. ovale. Hepatic hypnozoites may represent a form of parasite adaptation to climate. In temperate zones, this would enable the malarial parasite to "overwinter" in the human host. This strategy would prove advantageous when climatic conditions limit the activity of the mosquito vector. After a dormancy period between 6 and 12 months, hypnozoites become active and produce tissue schizonts.
Upon maturation, tissue schizonts rupture and merozoites are released into the bloodstream. The merozoites then infect RBCs, in which the second phase of asexual reproduction occurs. Intra-erythrocytic asexual replication is also common to all Plasmodium species. P. falciparum and P. malariae may invade erythrocytes of any age, whereas P. vivax and P. ovale selectively parasitize only young RBCs. Younger RBCs maintain their full complement of cytoplasmic membrane and expand with the growth of the organism. Older RBCs infected with either P. falciparum or P. malariae fail to expand with the growth of the parasite and remain normocytic compared with uninfected RBCs. These features are useful in the laboratory differentiation of Plasmodium species.
After RBC infection, another cycle of asexual replication occurs. Initially, a ring form develops, followed by differentiation into an amoeboid trophozoite form. This is followed by development of an intra-erythrocytic schizont, which contains many merozoites. This phase results in a 6- to 32-fold asexual amplification of the organism for each infected RBC. The number of merozoites produced in the intra-erythrocytic schizont varies between species. Schizonts present in the blood smear are useful for speciation. The developing parasites metabolize glucose and use RBC hemoglobin. The parasitic use of hemoglobin produces the characteristic hemozoin pigment as a waste product.
The erythrocyte-based asexual reproduction cycle culminates with RBC rupture. Merozoites are released into the bloodstream, and erythrocytes are infected again. This cycle of erythrocyte infection, merozoite replication, and RBC rupture is repetitive and may become highly synchronized. This synchronization is most classically seen in benign tertian malaria caused by P. vivax. Rupture of RBCs and release of merozoites correlate with the clinical symptoms of malaria. The RBC-based reproduction cycle of P. vivax and P. ovale occurs every 48 hours, whereas the erythrocytic cycle of P. falciparum occurs between 36 and 48 hours. The erythrocytic cycle of P. malariae occurs approximately every 72 hours.
The RBC-infecting merozoite may alternatively differentiate into either a microgametocyte or macrogametocyte. These gametocytes may be ingested by the female Anopheles mosquito during a blood meal. Fusion of the gametocytes takes place within the gut of the mosquito. The diploid zygote matures and invades the gut wall. Meiotic division ensues, which results in haploid sporozoites. The sporozoites migrate to the mosquito's salivary gland to complete the parasitic cycle.
| Morphologic feature | P. falciparum | P. malariae | P. vivax/P. ovale |
|---|---|---|---|
| Infected RBC size | Normocellular | Normocellular | Increased |
| RBC stippling | Coarse, comma-like dots occasionally present (Maurer's dots) | None present | Fine stippling (Schuffner's dots - P. vivax; James' stippling - P. ovale) |
| Parasite load | Often high | Often low | Intermediate |
| > 1 organism per cell | Common | Low | Occasional |
| Appliqué forms | Present | Usually absent | Usually absent |
| Advanced forms present | Usually absent, except in severe disease | Present | Present |
| Amoeboid forms | Not applicable | Basket, band, and indistinct amoeboid forms | Indistinct forms |
| Number of merozoites per cell | Not applicable | 6-12 (average 8) | P. vivax: 12-24 (average 16); P. ovale: 8-12 (average 8) |
| Amount of RBC occupied by schizont | Not applicable | Entire cell | P. vivax: entire cell; P. ovale: fills two-thirds of cell |
| Distinctive "banana-shaped" gametocyte | Present | Absent | Absent |
| Cycle of fever | Usually without an established cycle | Every 72 hours | Every 48 hours |
| Hypnozoites | Absent | Absent | Present |
Notes: Knowledge of the Plasmodium species endemic to the area where the patient contracted malaria is useful for narrowing the diagnostic possibilities. In non-endemic areas, relapse due to hypnozoites of P. vivax or P. ovale is often demonstrated by reactivation several months after leaving an endemic region.
| Species | Typical clinical pattern |
|---|---|
| P. vivax/P. ovale | Cyclical episodes consisting of chills followed by fever, which is followed by defervescence and diaphoresis; cyclical every 48 hours. |
| P. malariae | Cyclical episodes consisting of chills followed by fever, which is followed by defervescence and diaphoresis; cyclical every 72 hours; possible immune complex-mediated glomerulonephritis. |
| P. falciparum | Continuous fevers with irregular spikes; possible hyperparasitemia with microvascular damage and compromise. This is a medical emergency in the non-immune. Microvascular compromise may lead to central nervous system damage, renal and pulmonary failure, and death. |
| Indication | Population | Regimen type | Regimen details |
|---|---|---|---|
| P. falciparum malaria from areas with chloroquine resistance | Children | First choice | Mefloquine, 25 mg/kg, not to exceed the adult dosage, PO, taken with ≥ 8 oz of water (single dose). |
| P. falciparum malaria from areas with chloroquine resistance | Adults | First choice | Mefloquine, five 250-mg tablets (1250 mg) PO, with ≥ 8 oz of water (single dose). |
| P. falciparum malaria from areas with chloroquine resistance | Children | Second choice | Quinine sulfate, 25 mg/kg/day PO with doxycycline3, 2 mg/kg/day for 7 days, given with the quinine; or followed by pyrimethamine-sulfadoxine (0.25 tablet: age < 1 year; 0.5 tablet, age 1-3 years; 1.0 tablet, age 4-8 years; 2 tablets, age 9-14 years; 3 tablets, age ≥ 15 years); or followed by clindamycin, 20-40 mg/kg/day in 3 divided doses. |
| P. falciparum malaria from areas with chloroquine resistance | Adults | Second choice | Quinine sulfate, 650 mg PO every 8 hours for 3-7 days, with one of the following: doxycycline, 100 mg twice daily for 7 days; or followed by 3 pyrimethamine-sulfadoxine tablets; or followed by clindamycin, 900 mg three times a day for 5 days. |
| P. falciparum malaria (severe; parenteral therapy) | Children | Parenteral therapy | Quinine dihydrochloride, 20 mg of salt/kg IV loading dose in 5% dextrose given over 4 hours, followed by 10 mg of salt/kg given over 2-4 hours every 8 hours (maximum dose, 1800 mg/day); or quinidine gluconate, 10 mg salt/kg loading dose in normal saline, with slow infusion lasting 1-2 hours (maximum dose, 600 mg), followed by continuous infusion at 0.02 mg/kg/min. |
| P. falciparum malaria (severe; parenteral therapy) | Adults | Parenteral therapy | Quinine dihydrochloride, 20 mg of salt/kg IV loading dose in 5% dextrose given over 4 hours, followed by 10 mg of salt/kg given over 2-4 hours every 8 hours (maximum dose, 1800 mg/day); or quinidine gluconate, 10 mg salt/kg loading dose in normal saline, with slow infusion lasting 1-2 hours (maximum dose, 600 mg), followed by continuous infusion at 0.02 mg/kg/min. |
| Malaria caused by P. vivax, P. ovale, P. malariae, and chloroquine-sensitive P. falciparum | Children | First choice | Chloroquine, 10 mg base/kg PO loading dose (not to exceed 600 mg base), followed by 5 mg base/kg (not to exceed 300 mg base) given 6 hours after the first dose and again on days 2 and 3. |
| Malaria caused by P. vivax, P. ovale, P. malariae, and chloroquine-sensitive P. falciparum | Adults | First choice | Chloroquine, 600 mg base (1000 mg chloroquine phosphate) PO loading dose, followed by 300 mg base given 6 hours after the first dose and again on days 2 and 3. |
| Latent disease caused by P. vivax/P. ovale | Children | First choice | Primaquine phosphate, 0.3 mg base (0.5 mg salt)/kg/day for 14 days. |
| Latent disease caused by P. vivax/P. ovale | Adults | First choice | Primaquine phosphate, 15.3 mg base (26.5 mg salt) once daily PO for 14 days, or 45 mg base (79 mg salt) once weekly for 8 weeks. |
- Severe falciparum malaria should be treated with parenteral therapy; mefloquine should not be used for the treatment of severe falciparum malaria, since there is no parenteral formulation. Options include quinine (as above), quinidine, artesunate, and artemether.
- Exchange transfusion may be life-saving in non-immune patients with severe falciparum malaria and is indicated if parasitemia is > 30% or if parasitemia is > 10% and poor prognostic factors are present (i.e., elderly, schizonts in peripheral blood), if there are severe systemic manifestations (i.e., cerebral malaria, pulmonary or renal failure), or if therapeutic failure occurs.
- Do not use doxycycline in pregnant women or in children < 8 years of age.
Treatment recommendations and drug-resistance patterns change over time. Regimens for malaria should always be selected and monitored by clinicians familiar with current guidelines; patients should not attempt self-treatment.
| Category | Measure |
|---|---|
| Vector control | Avoid mosquito-infested areas. |
| Vector control | Wear protective clothing during evening and nighttime hours. |
| Vector control | Use mosquito repellent (containing 30-35% DEET for adults or 6-10% DEET for children). |
| Vector control | Spray bedclothes and mosquito netting with the insect repellent permethrin. |
| Vector control | Unless absolutely necessary, pregnant women should not travel to P. falciparum-endemic areas. |
| Prophylactic measures | Chloroquine remains the drug of choice in areas without known chloroquine resistance. |
| Prophylactic measures | Mefloquine is used in areas with known chloroquine-resistant strains. |
| Prophylactic measures | Doxycycline should be used when mefloquine cannot be taken, except in pregnant women, children < 8 years old, or those who are hypersensitive to doxycycline. |
| Prophylactic measures | Chloroquine and proguanil should be used only for patients who cannot take mefloquine or doxycycline. |
| Emergency self-treatment of possible malaria | Individuals using chloroquine prophylaxis in areas where chloroquine-resistant strains may reside must have one or more treatment doses of Fansidar (25 mg pyrimethamine + 500 mg sulfadoxine/tablet) (adult dosage: 3 tablets PO as a single dose; pediatric dosage: 5-10 kg, 1/2 tablet; 11-20 kg, 1 tablet; 21-30 kg, 1 1/2 tablets; 31-45 kg, 2 tablets; > 45 kg, adult dose). |
| Category | Clinical features |
|---|---|
| More common | Asymptomatic. |
| Less common | Mild infection: myalgia, low-grade fever with chills, fatigue, nausea, headache. Severe infection (more common in splenectomized, elderly, or immunocompromised patients): hemolytic anemia (with jaundice and dark urine), exacerbation of the above symptoms. |
| Population | Regimen type | Regimen details |
|---|---|---|
| Children | First choice | Clindamycin (20 mg/kg/day) for 7-10 days, plus quinine (25 mg/kg/day PO) taken for 7-10 days. |
| Adults | First choice | Clindamycin (300-600 mg every 6 hours) plus quinine (650 mg PO every 6-8 hours) taken for 7-10 days. |
Therapy for babesiosis should be guided by clinicians experienced in managing parasitic infections, as disease severity and host factors can significantly influence treatment choices.
| Category | Measure |
|---|---|
| Prophylactic measure | Avoid tick-infested areas. |
| Prophylactic measure | Use appropriate clothing and tick repellents if avoidance is impractical. |
| Prophylactic measure | Perform a body and scalp search for ticks on leaving infested areas. |

















